EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Interstitial lung abnormalities: a mechanistic window into early fibrotic lung disease

Brintha Selvarajah, Durdica Buconjic, Richard J. Hewitt

Frontiers in Medicine · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Interstitial lung abnormalities (ILAs) are incidental, non-dependent parenchymal abnormalities detected on chest computed tomography (CT) in individuals without a diagnosis of interstitial lung disease (ILD). Once regarded as non-specific or age-related findings, ILAs are increasingly recognized as clinically relevant entities associated with progression to fibrotic ILD and increased mortality. Emerging molecular and epidemiological evidence indicates that ILAs share key pathogenic pathways with idiopathic pulmonary fibrosis (IPF), the archetypal progressive fibrotic ILD, including alveolar epithelial cell (AEC) stress and injury, innate immune activation, dysregulated repair, fibroblast activation, extracellular matrix (ECM) remodeling, and aging-associated cellular dysfunction. These observations suggest that ILAs may represent the early stage in the continuum of fibrotic lung disease. As such, ILAs provide a valuable opportunity to uncover early disease mechanisms and novel therapeutic targets and enable identification of individuals at increased risk of progression before clinically overt ILD develops. This mini review summarizes emerging mechanistic insights into ILAs and discusses how understanding early disease biology may inform risk stratification and preventative therapeutic strategies.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Brintha Selvarajah, Durdica Buconjic, Richard J. Hewitt
Quelle
Frontiers in Medicine
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2296-858X
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Brintha Selvarajah, Durdica Buconjic, Richard J. Hewitt (2026). Interstitial lung abnormalities: a mechanistic window into early fibrotic lung disease. Frontiers in Medicine. https://doi.org/10.3389/fmed.2026.1867568
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1